SPOTLIGHT -
New Indication: Combination use with docetaxel for breast cancer; new black box
FDA Approves First Nonprescription Oral Contraceptive
Opill will be available in stores and online in the first quarter of 2024.
FDA Schedules Advisory Committee Meeting for OTC Contraceptive
If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.
FDA Approves Second Indication for Brexafemme
Brexafemme is a non-azole oral antifungal now approved to both treat and prevent recurrent yeast infections in women.
FDA Approves Liletta IUD to Prevent Pregnancy for 8 Years
The approval extends the use of Liletta for an additional two years. It is the only hormonal IUD approved for continuous use up to eight years.
Real-world Data Show Gardasil Protects Against Cervical, Non-Cervical Diseases
The greatest reductions were seen in girls who were vaccinated when they were adolescents, with up to 73% reduction in cervical pre-cancerous lesions.
FDA Postpones Advisory Committee Meeting for OTC Birth Control
